Neurocrine Biosciences Profit Margin

Neurocrine Biosciences (NBIX) currently reports a profit margin of 18.98% as of September 2026. That compares with 15.95% in the prior-year period — up 19.0% year over year. That is above the Healthcare sector average of 9.48%. Use the charts on this page to explore Neurocrine Biosciences's profit margin history and peer comparisons.

Neurocrine Biosciences's profit margin increased from 15.95% to 18.98% — a 19.0% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Neurocrine Biosciences's profit margin of 18.98% is higher than the Healthcare sector average of 9.48%. That is roughly 100.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Neurocrine Biosciences's current 18.98% should be judged against Healthcare norms (sector average: 9.48%) and against NBIX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 18.98%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 9.48%. From there, open related valuation or income-statement pages for Neurocrine Biosciences, and consider following NBIX for alerts when major investors trade the stock.